This study is for people with a type of lung cancer called non-small cell lung cancer (NSCLC). The goal is to test a drug called JNJ-86974680 with another drug named cetrelimab and radiation therapy to see what dose is safe. To join, you need to have advanced NSCLC, which means stage IIIB or IV, and meet other specific conditions. Some people need to have already tried certain cancer treatments.
If you have certain gene mutations, like changes in the EGFR, ALK, ROS1, or BRAF genes, you should have tried all available treatments targeting these genes first. Those in Part 1 and some in Part 2 of the study should have had treatments like PD-1 or PD-L1 therapy and chemotherapy.
Key Points:
- Participants must have specific types of advanced lung cancer.
- Previous cancer treatments might be required.
- People with active brain disease or certain infections cannot join.
How understandable was the trial content above?
Hard to understand
Easy to understand